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Abstract 
 
Cancer cells are widely known to be protected from apoptosis, which is a major hurdle to 
successful anti-cancer therapy. Over-expression of several anti-apoptotic proteins, or 
mutations in pro-apoptotic factors, has been recognized to confer such resistance. 
Development of new experimental strategies, such as in silico modeling of biological 
pathways, can increase our understanding of how abnormal regulation of apoptotic 
pathway in cancer cells can lead to tumour chemoresistance. Monte Carlo simulations are 
in particular well suited to study inherent variability, such as spatial heterogeneity and 
cell-to-cell variations in signaling reactions. Using this approach, often in combination 
with experimental validation of the computational model, we observed that large cell-to-
cell variability could explain the kinetics of apoptosis, which depends on the type of 
pathway and the strength of stress stimuli. Most importantly, Monte Carlo simulations of 
apoptotic signaling provides unexpected insights into the mechanisms of fractional cell 
killing induced by apoptosis-inducing agents, showing that not only variation in protein 
levels, but also inherent stochastic variability in signaling reactions, can lead to survival 
of a fraction of treated cancer cells. 
 
 
 
 
 
 
 
Introduction 
Induction of apoptosis by chemotherapeutics is considered as one of the major 
anti-cancer effects leading to inhibition of tumour growth. Over the past years our 
understanding of signaling pathways associated with induction of apoptosis, and 
knowledge on executioners of apoptosis, has substantially increased. Recently, cell-to-
cell stochastic variability has become central to apoptotic cell death signaling (1-6). 
Computational models are well suited to provide mechanistic insight into the system level 
regulations of apoptosis signaling and its large cellular variability. Studies that are 
possible using in silico approaches might be inaccessible by other techniques.  Recent 
novel findings in the area of apoptotic cell death signaling can have far-reaching 
implications in cancer biology and therapy. Our computational efforts, in synergy with 
parallel biological experiments, attempt to explore some of the fundamental issues in 
cancer biology within this new paradigm of apoptosis signaling.   
 
Developing computational models of cell death signaling for normal and cancer cells 
Monte Carlo models are generally suitable for simulating inherent stochasticity of 
signaling reactions in complex signaling pathways (1,7). Our recent work has elucidated 
that cell-to-cell stochastic variability is a fundamental characteristic of apoptosis 
signaling and a significant part of such variability can arise due to inherent stochastic 
fluctuations of chemical reactions (1,6,8,9). Even when the intrinsic stochastic variability 
is not dominant, Monte Carlo models have the advantage over ordinary differential 
equation (ODE) based models, as they can simulate spatial heterogeneity in an explicit 
manner. Examples of such spatial localizations in apoptosis signaling include 
translocation of activated Bax molecules onto mitochondrial outer membrane, release of 
cytochrome c from mitochondria to cytosol and redistribution of Apaf-1 in the cytosol, all 
of which depend on the cell type and the level of Bcl-2 proteins (10,11). In addition, we 
could easily incorporate realistic variations in (i) protein concentrations that may arise 
from stochastic gene regulations (3,12-15), and (ii) reaction rate constants, for example, 
due to variations in pH in the cytosolic environment. In our initial studies we grouped 
functionally redundant proteins so that a single representative protein simulates all 
proteins of similar function that are possibly expressed within a given cell type. For 
example, apoptotic inhibitor Bcl-2 captured the effect of all the inhibitory Bcl-2 like 
proteins (1,9). In the future we plan to simulate a more cell-type-specific signaling 
network of apoptosis, results of which can be readily compared with data obtained from 
parallel biological experiments for specific cell types. Such an expanded signaling 
network will often involve signaling species with low concentrations at initial time, or 
dynamically generate a few molecules due to specific inhibitory reactions, leading to 
inherent stochastic fluctuations that can be best studied using stochastic approaches.    
 
 
Differential signaling through extrinsic and intrinsic pathways of apoptosis 
Apoptosis is regulated through two distinct signaling pathways that are joined in a 
global loop structure as both pathways converge on activation of effecter Caspase-3 (10). 
The extrinsic (also called the type 1) pathway directly activates Caspase-3 by enzymatic 
reactions catalyzed by activated Caspase-8 molecules. The intrinsic (also called the type 
2) pathway is regulated by mitochondrial cytochrome c release and apoptosome 
formation. We can assume that three local signaling modules coordinate apoptosis in the 
type2 pathway (Figure 1).  Cell death can be induced by an apoptotic stimulus acting at 
any of the three different signaling modules (or right before them) of the apoptotic 
pathway (Figure 1): (i) death ligand binding and Caspase-8 activation, (ii) Bax activation 
by BH3 only proteins, (iii) Ca2+ release that activates only the post-mitochondrial events. 
Our initial studies showed that, for the case of Caspase-8 mediated apoptosis, 
concentration of active Caspase-8 decides between the two pathways of apoptosis. 
Membrane reorganization, such as clustering of death receptors in raft signaling domains, 
determines the level of Caspase-8 activation in a cell type specific manner (16). For large 
concentrations of Caspase-8, direct Caspase-3 activation occurs in a fast (~ minutes) 
deterministic manner. Such rapid activation of apoptosis has been observed in various 
cell types due to Fas ligand binding to Fas receptor (17). Decrease in the strength of an 
apoptotic stimulus begins to activate the intrinsic pathway (Figure 2), as the rate constant 
for Caspase-8-Bid interaction is higher than that for Caspase-8-capsase 3 association 
(1,18).  
 
 
Large cell-to-cell variability through the intrinsic (mitochondrial) pathway can 
explain slow apoptosis 
We observe slow apoptosis (~ hours) when low concentrations of Caspase-8 are 
used in our simulations. We also find large cell-to-cell stochastic variability in the case of 
slow apoptosis. Similar signaling behavior is observed, irrespective of Caspase-8 
concentration used, when we set the kinetic constants for the type 1 pathway to zero, 
confirming that slow apoptosis is a characteristic of the intrinsic pathway of apoptosis 
signaling. Such a study of pure type 2 apoptosis can be carried out in silico in a clean 
manner but will be difficult to achieve in biological experiments. When we perturbed the 
intrinsic apoptotic pathway downstream of Caspase-8 activation, we kept observing slow 
apoptosis with large cell-to-cell variability. Our results seem to explain very slow (~ 1 – 
100 hours) apoptosis observed experimentally under a variety of conditions, for various 
types of cells and apoptotic stimuli, including under oxidative stress (2-6,9,10,19,20).  
Additional variations in protein concentrations in our simulations act in tandem with 
intrinsic stochasticity of signaling reactions to enhance cell-to-cell variability in 
apoptosis. Caspase-3 activation occurs in an all-or-none (digital) manner for single cells 
implicating signaling amplification of a weak stimulus through the intrinsic pathway. 
However, the information of strength of the stimulus is contained in the time-to-death and 
its cell-to-cell variability.  Large cell-to-cell variability with all-or-none type Caspase-3 
activation, as observed in our simulations, resulted in bimodal probability distributions 
for Caspase-3 activation that are thought to be characteristic of apoptosis signaling 
through the intrinsic pathway (1). Later experiments confirmed existence of such bimodal 
probability distributions in Caspase-3 activation (2,3,6,9). 
 
Minimal model of a signaling network demonstrates cell-to-cell variability in 
apoptosis in a cell-type independent manner  
In parallel, we derived a minimal model of a signaling network that is designed to 
sense an external stimulus and respond to it in an adaptive manner (8). This minimal 
network is derived based on some simple assumptions on its signaling response without 
any prior knowledge of the apoptotic pathway. A three-step fast-slow-fast pathway in the 
minimal network was shown to be sufficient to generate large cell-to-cell variability as 
observed in our Monte Carlo simulations of the intrinsic pathway of apoptosis (1). This 
minimal network also captures the change from rapid deterministic to slow stochastic 
signaling as the strength of the stimuli is varied, and a quantitative estimation of the 
threshold stimulus is obtained. This could be potentially important if one wants to 
engineer cancer cells to convert from type 2 to type 1 for fast apoptotic activation. The 
crucial slow reaction in the intermediate step of the minimal network can mimic the slow 
activation of Bax or the apoptosome formation in apoptosis signaling. Thus we can infer 
that some of the pertinent qualitative features of apoptosis signaling, as observed in our 
Monte Carlo simulations, are cell type independent. Such a conclusion is significant 
given the fact that cellular protein levels and even the type of molecules present in the 
apoptotic pathways vary significantly among cell types (3,10,12). Cancer cells are known 
to over-express a variety of apoptotic inhibitors, which confer them unusual resistance to 
apoptosis (21-24). The level of over-expression varies significantly among cancer sub-
types and even among patients having the similar sub-types (25,26).  
 
How apoptotic inhibitors provide protection to cancer cells: implications for cancer 
therapy  
In a recent study we have shown that over-expression of Bcl-2 like proteins can 
slow down apoptosis and increase cell-to-cell stochastic variability (9). A high Bcl-2 
level allows activation of only a few Bax molecules under apoptotic stimuli and thus 
dynamically generates mechanisms for stochastic fluctuations caused by small number of 
molecules. Interestingly, cancer cells are often primed for death by increasing the levels 
of apoptotic BH3 proteins but apoptosis in such cells is kept in check by continuous 
inhibition by anti-apoptotic Bcl-2 like proteins (22-24). Bcl-2 binds with several pro-
apoptotic molecules creating a local loop structure (signaling module 2) in the intrinsic 
pathway that leads to non-linear and stochastic effects in its inhibitory action. Our 
simulations demonstrate that, beyond a threshold level, Bcl-2 imparts a strong inhibitory 
effect on apoptosis and thus can explain apoptosis resistance of cancer cells. For normal 
cells, having over-expressed Bcl-2 proteins, prolonged time-to-death might provide an 
opportunity for a particularly slow cell to acquire tumor initiating features. Behavior 
similar to tBid-Bcl-2-Bax signaling (in module 2) might be observed downstream of 
mitochondria (in signaling module 3) where higher Apaf-1 level might make cancer cells 
prone to apoptotic death, but such an effect can be negated by dominant effect of 
increased XIAP levels (27). XIAP also has multiple binding partners in a local loop 
network structure and contributes to generation of highly non-linear and stochastic 
signaling.  Hence pre- and post- mitochondrial events in the intrinsic pathway are heavily 
regulated by two different loop network structures in two distinct signaling modules 
(Figure 1).  Computational models are well suited to elucidate mechanisms of non-linear 
and stochastic signaling through those signaling modules. As a result, such models can 
help design optimal strategies to perturb those signaling modules by making use of the 
inherent apoptotic vulnerability of cancer cells. Initial simulations show increased cell 
death only for cancer cells having over-expressed BH3 protein Bid (unpublished 
observations), under a single agent treatment scenario such as under the action of Bcl-2 
inhibitor HA14-1 (28-30). Our computational studies can clarify the basis of such 
inherent vulnerability of cancer cells for all three signaling modules (Figure 1). However, 
targeting only a single module (Figure 1), for example ligation of death receptors at the 
signaling module 1, will provide an opportunity for a significant number of cells to 
escape death. Such fractional killing of cancer cells occurs not only due to cellular 
variations in protein levels but also from inherent stochastic variability in signaling 
reactions (9). Computational modeling was well suited to establish that inherent 
stochastic variability by itself, even when all the other cellular parameters remain 
identical, can generate large cell-to-cell variability comparable to that observed in 
apoptosis activation experiments (9). Such large cell-to-cell variability in time-to-death 
provides an opportunity for opposing growth signals to up-regulate downstream apoptotic 
inhibitors such as XIAP. This is particularly relevant as apoptosis activation under 
chemotherapeutic treatment can be slow enough to allow synthesis of inhibitor proteins 
of varying concentrations through stochastic gene regulations. Targeting multiple 
signaling modules simultaneously using combinatorial treatments can be effective in 
reducing stochastic effects and fractional killing of cancer cells. Computational studies 
can provide us with a range of concentrations for optimal induction of apoptosis in a 
combinatorial treatment scenario and can guide the design of biological experiments. We 
are currently exploring the combined effect of HA14-1, an inhibitor of Bcl-2 (28-30), and 
embelin (27), an inhibitor of XIAP, that can induce apoptotic collapse in cancer cells.  
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Figures  
 
Figure 1: Schematics of the apoptosis signaling pathway that indicates existence of three 
distinct signaling modules in the intrinsic pathway of apoptosis. Apoptosis can be 
activated at various locations in the intrinsic pathway. We also show some of the targets 
of cancer drugs in that pathway.   
 
 
Figure 2: Time course of caspase-3 activation for low concentration of caspase-8 (< 5 
nanomolar). Data is shown for five individual cells. Arrow indicates switch to the 
intrinsic pathway of apoptosis at the level of single cells.                
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